To evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic steatohepatitis
JKB-121 is a long-acting small molecule that is efficacious as a weak antagonist at the TLR-4 receptor. It is a non-selective opioid antagonist which has been shown to prevent the lipopolysaccharide (LPS) induced inflammatory liver injury in a methionine/choline deficient diet fed rat model of nonalcoholic fatty liver disease. In vitro, JKB-121 neutralized or reduced the LPS-induced release of inflammatory cytokines, deactivated hepatic stellate cells, inhibited hepatic stellate cell proliferation, and collagen expression. Inhibition of the TLR4 signaling pathway may provide an effective therapy in the prevention of inflammatory hepatic injury and hepatic fibrosis in patients with nonalcoholic steatohepatitis. This study will evaluate the safety and potential efficacy of two dose levels of JKB-121 (5 mg twice daily and 10 mg twice daily) in reducing liver fat and/or liver biochemistry compared to placebo in patients with biopsy-proven nonalcoholic steatohepatitis.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
65
Digestive Disease Specialists of the Southeast
Dothan, Alabama, United States
Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Digestive Associates
Las Vegas, Nevada, United States
Duke University
Durham, North Carolina, United States
Analysis of MRI-PDFF Change From Baseline to Week 24 (Per Protocol Population)
Time frame: Baseline to week 24
Analysis of MRI-PDFF Change From Baseline to Week 12 (Per Protocol Population)
Time frame: Baseline to Week 12
Analysis of ALT Change From Baseline to Week 24 (Per Protocol Population)
Time frame: Baseline to week 24
Analysis of ALT Change From Baseline to Week 12 (Per Protocol Population)
Time frame: Baseline to week 12
Time to Remission (in Weeks)
Time to remission is the time in weeks from randomization to liver function remission, defined as two consecutive ALT values within normal range (\<40 U/L) during the treatment period.
Time frame: 24 weeks
Change in BMI (Body Mass Index)
Time frame: Baseline, week 24
Change in Hemoglobin A1C
Time frame: Baseline, week 24
Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR)
HOMA-IR was calculated according to the formula: fasting insulin (microU/L) x fasting glucose (nmol/L)/22.5. Optimal Range: 1.0 (0.5-1.4). Lower values represent a better outcome.
Time frame: Baseline, week 24
Percent Change in Cholesterol
Time frame: Baseline, week 24
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Digestive Disease Specialists
Cincinnati, Ohio, United States
Brook Army Medical Center
Houston, Texas, United States
University of Virginia Health Systems
Charlottesville, Virginia, United States
Medical College of Virginia
Richmond, Virginia, United States
Percent Change in Triglycerides
Time frame: Baseline, week 24
Percent Change in Low Density Lipoprotein (LDL) Cholesterol
Time frame: Baseline, week 24
Percent Change in High Density Lipoprotein (HDL)
Time frame: Baseline, week 24
Mean Serum Aspartate Aminotransferase (AST)
Time frame: weeks 4, 8, 12, 16, 20, and 24
Mean Serum Alanine Aminotransferase (ALT)
Time frame: weeks 4, 8, 12, 16, 20, and 24
Mean Serum Gamma-glutamyl Transpeptidase (GGT)
Time frame: weeks 4, 8, 12, 16, 20, and 24
Number of Subjects With ALT in Normal Range at Week 24
Normal range is \<40 U/L
Time frame: Week 24
Maximum Observed Concentrations (Cmax)
Time frame: pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours
Minimum Observed Concentration (Cmin)
Time frame: pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours
Area Under Concentration-time (AUC)
Time frame: pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours
Half-life
Time frame: pre-dose and at 0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12, and 24 hours